Skip to content

NERVGEN PHARMA CORP.

NGEN

CIK 0001751912

← back to feed
Revenue (TTM)
—
FY Dec 2025
Net Income (TTM)
−44.12M
−81.9% YoY FY Dec 2025
EPS Diluted (TTM)
−0.61
−69.4% YoY FY Dec 2025
Gross Margin
—
FY Dec 2025
Operating Margin
—
FY Dec 2025
Net Margin
—
FY Dec 2025
Free Cash Flow (TTM)
—
FY Dec 2025
Cash
22.07M
FY Dec 2025
Total Debt
—
FY Dec 2025
Shares Outstanding
79.65M sh
FY Dec 2025

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings